Years

18.07.2017

The European Parliament adopted a resolution on the EU’s response to HIV/AIDS, Tuberculosis and Hepatitis C

The European Parliament adopted a resolution on the EU’s response to HIV/AIDS, Tuberculosis and Hepatitis C, prepared by its Committee on the Environment, Public Health and Food Safety.

Learn more

18.07.2017

NASH-CORE findings to be unveiled in conjunction with the First EASL NAFLD Summit

The global prevalence of non-alcoholic fatty liver disease (NAFLD) is 25%. It is considered to be endemic in Europe and a major potential threat to public health. Yet it appears to receive very limited attention. EASL International Liver Foundation aims to place the spotlight on NALFD and take the first important step needed to generate a call to action by developing an understanding of what government and key stakeholders such as medical associations and patient groups are currently doing.

Learn more

18.07.2017

Supporting Viral Hepatitis elimination in Mongolia

Mongolia has the world’s highest rate of liver cancer mortality; nearly eight times the global average. The prevalence of chronic viral hepatitis B, C, and D is at endemic level, and constitutes the main reason cause of Mongolia’s world-leading liver cancer mortality rate. To tackle this deadly crisis, the Onom Foundation, Patient and Civil Society Council, Mongolian Gastroenterology Association, and Mongolian Society of Hepatology launched the Hepatitis Prevention, Control, and Elimination (HPCE).

Learn more

18.07.2017

Elimination of Viral Hepatitis in Chronic Kidney Disease patients: a call to action

We are honoured to announce that we have joined forces with the European Renal Association- European Dialysis and Transplant Association (ERA-EDTA) to bring together expert Hepatologists and Nephrologists to eliminate viral hepatitis among patients with chronic kidney disease (CKD).

Learn more

18.07.2017

Education

To solve the huge challenges we face as a society we need to help everyone in the field maximize the full potential of their talents and intellect. Then they can mobilize those skills to help us solve our most difficult problems. That’s why education is central to us achieving our goals.

Learn more

18.07.2017

Research & Development

We act as a driving force; supporting some of the greatest minds in science and medicine through... View Article

Learn more

18.07.2017

Public Awareness

We are promoting a liver-healthy lifestyle to the masses. 80% of liver disease is preventable. Yet every... View Article

Learn more

18.07.2017

Viral Hepatitis Elimination

We are taking a lead role in designing and implementing programs that can support the achievement of... View Article

Learn more

18.07.2017

The new scenario of HCV therapy in NHL patients”

What are the non-Hodgkin lymphoma subtypes most frequently associated with Hepatitis C Virus? Hepatitis C Virus (HCV) has been linked to a spectrum of lymphoproliferative disorders. HCV prevalence in patients with B-cell non-Hodgkin’s lymphoma (NHL) is approximately 15%, tenfold higher than that reported in general population (1.5%), with higher risk in countries with higher HCV prevalence.

Learn more

18.07.2017

Hepatitis E, a silent food-borne epidemic in Europe

What is the burden of Hepatitis E Virus? Hepatitis E virus (HEV) is the most common cause of acute viral hepatitis worldwide

Learn more

18.07.2017

Foundation’s Principles

Why did EASL decide to create the Foundation? The discussion on creating an EASL foundation has been running for many years, and possibly arguments have been changing over this period.

Learn more

18.07.2017

HCV and Chronic Kidney Disease: a reciprocal interplay

What are les liasons dangeroux between hepatitis C and kidneys? Hepatitis C virus (HCV) infection enhances on the one hand the risk of chronic kidney disease

Learn more
  • 1 of 2